Skip to main content

Graybug Vision, Inc. (GRAY)

NASDAQ: GRAY · IEX Real-Time Price · USD
3.67 -0.06 (-1.61%)
Sep 24, 2021 11:28 AM EDT - Market open
Market Cap75.77M
Revenue (ttm)n/a
Net Income (ttm)-35.42M
Shares Out21.28M
EPS (ttm)-2.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume28,398
Open3.74
Previous Close3.73
Day's Range3.65 - 3.75
52-Week Range3.43 - 37.88
Betan/a
AnalystsStrong Buy
Price Target4.75 (+29.4%)
Est. Earnings DateNov 10, 2021

About GRAY

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopath...

IndustryBiotechnology
IPO DateSep 25, 2020
Employees27
Stock ExchangeNASDAQ
Ticker SymbolGRAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Graybug Vision stock is "Strong Buy." The 12-month stock price forecast is 4.75, which is an increase of 29.43% from the latest price.

Price Target
$4.75
(29.43% upside)
Analyst Consensus: Strong Buy

News

Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference

BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...

2 days ago - GlobeNewsWire

Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Dev...

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

1 month ago - GlobeNewsWire

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

1 month ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Graybug Vision (GRAY) Stock?

Investors need to pay close attention to Graybug Vision (GRAY) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Graybug Vision Shorts Got A Serious Squeeze: What's Next?

Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn't stop the stock from closing up 22% on Thursday and soaring fu...

3 months ago - Benzinga

Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD

Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet A...

Other symbols:AMD
4 months ago - Benzinga

Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...

4 months ago - GlobeNewsWire

3 Net Current Asset Value Stock Picks

There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised the...

Other symbols:GLYCODT
4 months ago - GuruFocus

Why Is Graybug Vision Stock Plunging Today?

Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mea...

6 months ago - Benzinga

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

6 months ago - GlobeNewsWire

Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

6 months ago - GlobeNewsWire

Graybug Vision to Participate in SVB Leerink Global Healthcare Conference

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

7 months ago - GlobeNewsWire

Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company's Executive Team

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

7 months ago - GlobeNewsWire

Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second ...

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

8 months ago - GlobeNewsWire

Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference

REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

10 months ago - GlobeNewsWire

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporat...

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

10 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

11 months ago - Seeking Alpha

Graybug Vision's stock open up 19%, then pares some gains

Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m.

11 months ago - Market Watch

Graybug Appoints Three New Members to its Board of Directors

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...

11 months ago - GlobeNewsWire

Graybug Vision prices upsized IPO at midpoint of expected range, raises $90 million

Graybug Vision Inc. GRAY, +2.59% said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share.

11 months ago - Market Watch

Graybug Vision Announces Pricing of Upsized Initial Public Offering

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...

11 months ago - GlobeNewsWire

Graybug Vision Readies $75 Million IPO Effort

Graybug Vision has filed to raise $75 million from the sale of its common stock in a U.S. IPO.

1 year ago - Seeking Alpha